Hongsheng Capital Closes First Close of Its Inaugural Market-Oriented Healthcare Fund, Advancing an 'Ecosystem + Empowerment' Investment Strategy

VCBeat (WeChat ID: vcbeat) has learned that Ariose Capital recently announced the first closing of its inaugural market-oriented healthcare fund, marking its entry into the investment period. The establishment of this fund has received support from multiple listed healthcare companies, private enterprises, and family offices, including Obio Technology (SH.688238), CareRay Medical (SZ.300326), Realbio Technology (SH.688217), Tianyi Medical (SZ.301097), Huakang Medical (SZ.301235), Jianhui Information (SH.605186), and Aupu Biologics (NQ.873758). This milestone signifies the launch of Ariose Capital’s closed-loop industrial investment model centered on “ecosystem + empowerment” in the healthcare sector.

This fund is oriented toward “hard tech,” focusing on early- to mid-stage investment opportunities. It leverages the industrial resources of listed healthcare companies to build Ariose Capital’s healthcare ecosystem. The fund prioritizes strategic partners of listed companies, upstream and downstream players in the industry chain, incubation of foundational technological innovations, and projects that extend product pipelines. By fully utilizing clinical and expert resources from top-tier hospitals, it aims to establish distinctive investment advantages characterized by professional technical assessment, relatively controllable valuations, and diversified exit pathways.Ariose Capital emphasizes a portfolio-based investment approach. For mid-stage projects, it will leverage ecosystem resources to uncover “under-the-radar” investment opportunities, prioritizing exit certainty and liquidity. For early-stage projects, it will tap into the industrial chain resources of listed companies to explore and incubate innovative ventures with high technological barriers, emphasizing diversified exit options and return on investment.

Domestic healthcare startups often encounter bottlenecks during the commercialization phase, a unique pain point in China’s healthcare industry, particularly in areas such as market access, clinical communication, and channel development. Leveraging its team’s extensive experience in the healthcare sector, Ariose Capital Management Limited aims to make “comprehensive post-investment empowerment” a distinctive advantage of its fund, thereby providing robust support to its portfolio companies. To address the needs of enterprises at various stages, Ariose Capital has introduced the “6-S” service philosophy, which includes: 1) capital operation services; 2) government affairs services; 3) commercial channel services; 4) distributor resource services; 5) clinical research liaison services; and 6) human resources liaison services. Through a professional post-investment management system, the firm continuously enhances the comprehensive competitiveness of its portfolio companies while delivering superior returns to its fund investors.

Pan Oudong, Chairman of Obio TechnologyStatement: Rooted in the CDMO sector for cell and gene therapies, Obio Technology takes professional service as its mission. We are honored to partner with the Ariose Capital team, leveraging financial strength to strategically invest in innovative biotechnologies. We are committed to contributing our share, fulfilling our responsibilities, and delivering tangible results to advance the development of the human life and health industry.

Yuan Zheng, Chairman of KellytaiIt was stated that Kellytai focuses on the medical device industry and has successfully established a mature ecosystem incubation model. In recent years, multiple startups have successfully entered the capital markets. Leveraging its existing ecosystem resources, Kellytai will actively support Ariose Capital Management Limited in deploying within the medical device sector to jointly incubate more high-quality projects.

Xiong Hui, Chairman of RayAgile GenomicsIt indicates that in the process of investment homogenization, "post-investment empowerment" increasingly reflects the differentiation of investment institutions. The core team of Ariose Capital Management Limited was once an investor in Rayone, actively providing assistance and empowerment during the company's development. We hope to assist Ariose in bringing "post-investment empowerment" to more entrepreneurial teams, injecting new momentum into the development of the medical and health industry.

Wu Zhimin, Chairman of Tianyi MedicalIt was stated that Tianyi Medical has been deeply engaged in the fields of blood purification and critical care, gradually establishing business development platforms both domestically and internationally, as well as an industrial platform for horizontal strategic expansion and resource empowerment. The company expressed its hope to work closely with Ariose Capital under the “industry + capital” dual-drive development model to pursue mutual growth, cultivate and incubate high-potential medical technology companies, and contribute to enhancing the level of healthcare in China.

Dai Jianwei, Chairman of Jianhui InformationStatement: It is a great honor to participate in the investment of the Ariose Capital Healthcare Fund. As seasoned experts in the healthcare industry, the Ariose team possesses keen insights into market dynamics. We believe that through a model combining capital with strategic empowerment, we can introduce distinct investment philosophies and drive value enhancement in healthcare innovation investments. Meanwhile, through collaboration with numerous publicly listed healthcare companies, we look forward to fostering greater synergy and generating impactful innovations.

Tan Pingtao, Chairman of Huakang MedicalIt stated: As a listed company specializing in the integration of medical purification systems, Huakang Medical provides full-process technical services for specialized hospital construction projects. Through this investment by Ariose Capital, the parties aim to jointly build a healthcare ecosystem and explore new avenues for expanding Huakang Medical’s upstream and downstream business.

Xu Jianxin, Chairman of Aupu BioIt stated: “Aupu Bio has been dedicated to the field of medical point-of-care testing (POCT) for over two decades, focusing on digital-intelligent diagnostics and Internet-plus new technologies, and has established a core technology platform with nearly 100 independent intellectual property rights. We are honored to join hands with the Ariose team and several listed companies to accelerate the integration and conversion of ‘capital + technology + market,’ striving to become a leading brand among Chinese medical diagnostic enterprises, and working together with the Ariose team to make our modest contribution to human health.”

Ariose Capital specializes in equity investments within the healthcare and medical sectors, with total assets under management exceeding RMB 1 billion. Its limited partners include more than ten publicly listed healthcare companies, state-owned enterprises, market-oriented fund-of-funds, and local governments. The management team comprises industry leaders from top-tier central state-owned pharmaceutical distribution enterprises, private equity funds, and publicly listed healthcare companies. The core team has over 20 years of deep expertise in the operation of the healthcare and wellness industry, along with more than 10 years of experience in equity investment and management. Ariose Capital distinguishes itself through its “Ecosystem Investment Strategy” and “Comprehensive Post-Investment Value-Added Services.” It leverages the advantageous resources of industry-listed companies and its team to build a healthcare ecosystem, conducting in-depth investment layouts closely aligned with these ecosystem resources. Meanwhile, it fully utilizes ecosystem resources to provide a series of post-investment value-added services to portfolio companies, facilitating their robust development and delivering superior returns to the fund’s investors.